Loratadine (Loratadine Ascend)
Loratadine
Ascend Laboratories (Pty) Ltd
Registration
- Applicant
- Ascend Laboratories (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Loratadine syrup ascend EACH 5,0 ml SOLUTION CONTAINS LORATADINE 5,0 mg | Syrup | 56114956/5.7.1/1149 | Registered | Not determined | None |
| Loratadine tablet ascend Each Tablet contains: Loratadine 10,0 mg | Tablet | 57029857/5.7.1/0298 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S1: Loratadine
Consolidated Schedules 06 July 2026, line 805
2 of 2 approved products with this ingredient carry S2 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate
Drag to rotate. Structure from PubChem CID 3957.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.